![These highlights do not include all the information needed to use ENTRESTO safely and effectively. See full prescribing information for ENTRESTO. ENTRESTO® (sacubitril and valsartan) tablets, for oral use Initial U.S. Approval: These highlights do not include all the information needed to use ENTRESTO safely and effectively. See full prescribing information for ENTRESTO. ENTRESTO® (sacubitril and valsartan) tablets, for oral use Initial U.S. Approval:](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=ENTRESTO-08.jpg&id=622573)
These highlights do not include all the information needed to use ENTRESTO safely and effectively. See full prescribing information for ENTRESTO. ENTRESTO® (sacubitril and valsartan) tablets, for oral use Initial U.S. Approval:
Entresto Coupons and Discounts: Get the Best Price for Entresto using This Savings Card (Sacubitril/Valsartan Coupon) | Miami Herald
البورد العراقي للصيدلة السريرية - 📝Entresto contains sacubitril (24 mg, 49 mg, or 97 mg) and valsartan (26 mg, 51 mg, or 103 mg). Use caution when prescribing since dosing in clinical
![Entresto heart failure drug. Packaging for the combination drug sacubitril and valsarta, sold here under the brand name Entrasto, and developed and ma Stock Photo - Alamy Entresto heart failure drug. Packaging for the combination drug sacubitril and valsarta, sold here under the brand name Entrasto, and developed and ma Stock Photo - Alamy](https://c8.alamy.com/comp/2ADD8H5/entresto-heart-failure-drug-packaging-for-the-combination-drug-sacubitril-and-valsarta-sold-here-under-the-brand-name-entrasto-and-developed-and-ma-2ADD8H5.jpg)
Entresto heart failure drug. Packaging for the combination drug sacubitril and valsarta, sold here under the brand name Entrasto, and developed and ma Stock Photo - Alamy
Study Shows Entresto (Sacubitril / valsartan) Improves Physical, Social Activity in Heart Failure Patients - Novartis
![New analyses show Novartis' EntrestoTM reduced cardiovascular death or hospitalization forheart failure, consistently benefitting patients with reduced ejection fractionregardless of prior heart failure hospital admissions or background therapy | Novartis New analyses show Novartis' EntrestoTM reduced cardiovascular death or hospitalization forheart failure, consistently benefitting patients with reduced ejection fractionregardless of prior heart failure hospital admissions or background therapy | Novartis](https://novartis.gcs-web.com/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2017/03/31/5-41-45/2138Photo1.png?itok=3HOFVrIh)